Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol: ATRI-001

Brief description of study

Subjects who are currently participating in the ADNI-2 research study as well as new subjects are invited to another study. ADNI-w was designed to look at the relationship between clinical, cognitive (having to do with memory and thinking), imaging, genetic and biomarker tests over time, in order to understand the full spectrum of Alzheimer’s disease (AD) from its earliest stages. Genetic information is the information passed from parent to child that makes each individual unique. Biomarkers are indicators of biological processes that can be measured in tissue samples and bodily fluids. The ADNI-3 research study will continue to collect and store more of this kind of research data. Data from this research will continue to be used in the development of future research studies that focus on the treatment of AD at an early stage.


Clinical Study Identifier: s16-02297
ClinicalTrials.gov Identifier: NCT02854033
Principal Investigator: Martin Sadowski
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.